arrow
V

Vedang Murthy

Tata Memorial Centre
H指数:41
被引数:8,205

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Interpretable machine learning identifies health system levers for survival outcomes of patients with prostate cancer

可解释机器学习识别影响前列腺癌患者生存结果的健康系统杠杆

2026-10-020
PRE
Randomized trial of adjuvant 5-FU-platinum versus paclitaxel-platinum for high-risk penile cancer

高危阴茎癌辅助治疗中5-FU-铂类与紫杉醇-铂类随机对照试验

2026-08-240
PRE
PACE-NODES: A phase III randomised trial of 5 fraction prostate stereotactic body radiotherapy (SBRT) versus 5 fraction prostate and pelvic nodal SBRT

PACE-NODES:一项比较5次分割前列腺立体定向体部放疗(SBRT)与5次分割前列腺和盆腔淋巴结SBRT的随机对照III期试验

2026-02-110
OAAI
Pre-PROTO-PRIME study: stereotactic body proton therapy to the prostate and pelvic nodes for high-risk and node-positive prostate cancer — feasibility, acute toxicity and dosimetric insights

PRE-PROTO-PRIME研究:前列腺和盆腔淋巴结的立体定向体部质子治疗用于高危和淋巴结阳性前列腺癌——可行性、急性毒性和剂量学见解

2025-11-210
OAAI
Gallium-68-Labeled Prostate-Specific Membrane Antigen Positron Emission Tomography/Computed Tomography Response in Pelvic Node-Positive Prostate Cancer After Definitive Radiation Therapy: Prognostic Implications

^{68}Ga标记的前列腺特异性膜抗原正电子发射断层扫描/计算机断层扫描在盆腔淋巴结阳性前列腺癌接受根治性放射治疗后的反应:预后意义

2025-10-010
PRE
Presentation and outcomes of second primary malignancies (SPMs) in locally advanced oral cavity squamous carcinoma (LA-OSCC): Secondary analysis of a phase III randomised control trial (NCT00193843)

局部晚期口腔鳞状细胞癌(LA-OSCC)中第二原发恶性肿瘤(SPMs)的表现及预后:一项III期随机对照试验(NCT00193843)的二次分析

2025-05-210
PRE
Bladder Adjuvant Radiation Therapy (BART): Acute and Late Toxicity From a Phase III Multicenter Randomized Controlled Trial
2025-03-010
PRE
Late Urinary Toxicity After Extreme or Moderate Hypofractionated Prostate Radiation Therapy in Patients With Prior Transurethral Resection of Prostate
2024-11-011
PRE